ACTIVIDADES

International Symposium on Hepatic Encephalopathy. Septiembre 2009.

Del 17/09/2009 al 19/09/2009

Programa de la actividad

JUEVES 17

09:10-10:10   “Andres T. Blei Lecture”
Roger F. Butterworth. Hôpital Saint-Luc C.H.U.M. Montreal, Canada.
Cerebral inflammation in liver failure.

Mechanisms of ammonia toxicity

10:10-10:40   Susanne Keiding. Aarhus University Hospital. Aarhus, Denmark.
Brain ammonia and energy metabolism in hepatic encephalopathy. Analysis by positron emission tomography.

10:40-11:10   Coffe Break

11:10-11:40   Dieter Häussinger. Heinrich-Heine-Universität. Düsseldorf, Germany.
Oxidation of RNA in hyperammonemia and hepatic encephalopathy.

11:40-12:10   Michael D. Norenberg. University of Miami School of Medicine. Miami, USA.
Role of NF-kB in ammonia toxicity.

12:10-12:40   Jan Albrecht. Medical Research Center, Polish Academy of Sciences. Warsaw, Poland.
Mechanisms of cell protection in ammonia neurotoxicity.

12:40-13:10   Magdalena Zielinska. Medical Research Center, Polish Academy of Sciences. Warsaw, Poland.
Modulation of the NO-cGMP pathway by glutamine.

13:10-13:25   Vairappan Balasubramaniyan.  University College London. London, United Kingdom.
Reduction in hyperammonemia with l-ornithine phenylacetate (OCR-002) in bile-duct-ligated (BDL) cirrhotic rats restores brain eNOS activity by modulating the DDAH-ADMA pathway.

13:25-15:00   Lunch

Neurotransmission
Chairman: Roger F. Butterworth

15:00-15:30   Javier Saez-Valero. Universidad Miguel Hernández-CSIC. Alicante, Spain.
Brain cholinergic alterations in liver failure. Role in cognitive function.The cannabinoids system in liver disease and hepatic encephalopathy.

15:30-16:00   Vicente Felipo. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Selective regional alterations in GABAergic tone in brain in chronic hyperammonemia in vivo. Role in cognitive impairment.

16:00-16:30   Coffe break

16:30-17:00   Samir Ahboucha. Hôpital Saint-Luc C.H.U.M. Montreal, Canada.
The neurosteroids system in hepatic encephalopathy.

17:00-17:30   Sophie Lotersztajn. Inserm U955, Hôpital Henri Mondor. Créteil, France.

VIERNES 18

Cerebral edema
Chairman: Jan Albrecht

09:00-09:30   Alejandro A. Rabinstein. Mayo Clinic, Rochester. Minnesota, USA.
Cerebral edema: types, mechanisms and treatments.

09:30-10:00   Rodrigo Jover. Hospital General de Alicante. Alicante, Spain.
Vasogenic and cytotoxic edema in patients with acute, chronic or acute on chronic liver disease.

10:00-10:30   Omar Cauli. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Vasogenic and cytotoxic edema in brain in animal models of acute or chronic hepatic encephalopathy and hyperammonemia.

10:30-11:00   Coffe break

11:00-11:30   N. Jan Shah. Forschungszentrum Jülich GmbH. Jülich, Germany.
Quantitative cerebral water content mapping in hepatic encephalopathy.

11:30-12:00   Rakesh K. Gupta. SGPGIMS. Lucknow, India.
Advances in the Magnetic resonance imaging in patients with liver failure and hepatic encephalopathy.

Acute liver failure
Chairman: Rodrigo Jover

12:00-12:30   Juan Cordoba. Hospital Vall d’Hebron. Barcelona. Spain
Metabonomic analysis of hepatic encephalopathy progression during acute liver failure

12:30-13:00   Finn S. Larsen. Rigshospitalet University Hospital of Copenhagen. Copenhagen, Denmark.
Cerebral hemodynamic alterations in acute liver failure. Underlying mechanisms and role in death.

13:00-14:30  Lunch

14:30-15:00   Rajiv Jalan. Royal Free and University College Medical School. London, UK.
Brain inflammation in acute liver failure and its relationship with intracranial hypertension and death.

15:00-15:15   Marc Oria. Hospital Vall d’Hebron. Barcelona, Spain.
Neurophysiologic disturbances in experimental HE are related to ammonia induced changes in brain metabolites and not to brain edema.  

15:15-15:45   Regina Rodrigo. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.

15:45-16:15   Julia Wendon. King's College Hospital. London, UK.
Intensive care management of acute liver failure.

16:15-16:45   Coffe break
 

Neurological alterations
Chair: Marsha Morgan

16:45-17:15   Andrea Stracciari. S. Orsola-Malpighi University Hospital. Bologna, Italy.
Cognitive functioning in chronic acquired hepatocerebral degeneration.

17:15-17:45  Andrea Kelly. Children's Hospital of Philadelphia. Philadelphia, USA
Hyperinsulinism/hyperammonemia syndrome: alterations in cerebral function and molecular mechanisms.

17:45-18:15    Christopher O. Record. Newcastle Upon Tyne Hospitals NHS Trust. Newcastle Upon Tyne, UK.
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion.

18:15-18:30   Sara Montagnese. University of Padua. Padua, Italy.
Hepatic encephalopathy: a different pathophysiology for different features?

SABADO 19

Neurological alterations
Chairman: Rajiv Jalan

09:00-09:30   Karin Weissenborn. Medizinische Hochschule Hannover. Hannover, Germany.
Cognitive alterations in patients with hepatic encephalopathy.

09:30-10:00   Marsha Morgan. The UCL Institute of Hepatology. London, UK.
Alterations in sleep and in circadian rhythms in patients with liver disease.

10:00-10:30   Jasmohan S. Bajaj. Virginia Commonwealth University and McGuire VA Medical Center. Richmond VA, USA.
Minimal hepatic encephalopathy and daily life.

10:30-11:00   Piero Amodio. University of Padova. Padova, Italy.
Electroencephalographic staging of hepatic encephalopathy.

11:00-11:30   Coffe break

Treatments
Chairman: Vicente Felipo

11:30-12:00   Andrew A. M. Morris. Royal Manchester Children’s Hospital. Manchester, UK.
Neonatal hyperammonemia, main causes and treatment.

12:00-12:30   Rajiv Jalan. Royal Free and University College Medical School. London, UK.
Ornithine-phenylacetate for the treatment of hyperammonemia and hepatic encephalopathy.

12:30-13:00   Mariano Malaguarnera. University of Catania. Catania, Italy.
Probiotics and acetylcarnitine in the treatment of minimal hepatic encephalopathy.

13:00-13:30   Ángeles Pérez-Pastor. Hospital Universitario de Valme. Sevilla, Spain.
Rifaximin for the treatment of hepatic encephalopathy